[go: up one dir, main page]

WO1993004086A1 - Recepteurs de produits finaux de glycosylation avancee et leurs utilisations - Google Patents

Recepteurs de produits finaux de glycosylation avancee et leurs utilisations Download PDF

Info

Publication number
WO1993004086A1
WO1993004086A1 PCT/US1992/007155 US9207155W WO9304086A1 WO 1993004086 A1 WO1993004086 A1 WO 1993004086A1 US 9207155 W US9207155 W US 9207155W WO 9304086 A1 WO9304086 A1 WO 9304086A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
age
bsa
proteins
molecular mass
Prior art date
Application number
PCT/US1992/007155
Other languages
English (en)
Inventor
Helen Vlassara
Zhi Yang
Anthony Cerami
Original Assignee
The Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/749,444 external-priority patent/US5202424A/en
Priority claimed from US07/749,438 external-priority patent/US5585344A/en
Application filed by The Rockefeller University filed Critical The Rockefeller University
Publication of WO1993004086A1 publication Critical patent/WO1993004086A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)

Definitions

  • the present invention relates generally to the nonenzymatic glycosylation of proteins, and particularly to the discovery of binding partners to advanced glycosylation endproducts such as AGE receptors, that may serve in the diagnosis and treatment of conditions in which the presence or activity of such advanced glycosylation endproducts may be implicated.
  • advanced glycosylation endproducts such as AGE receptors
  • Glucose and other reducing sugars attach non- enzymatically to the amino groups of proteins in a concentration-dependent manner. Over time, these initial Amadori adducts undergo further rearrangements, dehydrations and cross-linking with other proteins to accumulate as a family of complex structures which are referred to as Advanced Glycosylation Endproducts (AGEs) . Although this chemistry has been studied by food chemists for many years, it was only in the past decade that the presence of AGEs in living tissues has been established.
  • AGEs Advanced Glycosylation Endproducts
  • receptors are disclosed that may be derived from either rat liver membranes, or mesangial cells and that recognize and bind advanced glycosylation endproducts.
  • the receptors comprise at least one protein and possess at least one of the following characteristics:
  • a protein having a molecular mass of about 90 kD comprises at least one protein selected from the group consisting of a protein having a molecular mass of about 90 kD, a protein having a molecular mass of about 60 kD, a protein having a molecular mass of about 50 kD, a protein having a molecular mass of about 40 kD, and a protein having a molecular mass ranging from about 30 to about 35 kD, as determined by migration on SDS- PAGE.
  • the receptors are derived from rat liver membrane cells and possess the following characteristics:
  • proteins comprise at least two proteins, the first of said proteins having a molecular mass of about 90 kD and the second of said proteins having a molecular mass of about 60 kD as determined by their migration on SDS- PAGE.
  • the receptors are derived from mesangial cells and possess the following characteristics: A. they recognize and bind with the ligands AGE- BSA, AGE-RNAse and AGE-collagen I in a saturable fashion, having a binding affinity of 2.0 ⁇ 0.4 x 10 6 M "1 (500nM) ;
  • D they comprise at least one protein selected from the group consisting of a first protein having a molecular mass of about 50 kD, a second protein having a molecular mass of about 40 kD, and a third protein having a molecular mass of about 30-35 kD, as determined by their migration on SDS-PAGE.
  • the mesangial cell-derived receptors may comprise a substantially purified receptor reactive with advanced glycosylation endproducts, characterized as follows:
  • (A) it contains at least one proteins selected from the group consisting of a protein having a molecular mass of about
  • the individual proteins listed above have certain common characteristics, to the extent that the proteins derived from rat liver cells are also expressed on both rat monocytes and macrophages, and both proteins copurify from elutions based, respectively, on an AGE ligand affinity column, an anion exchange column, and a hydroxylapatite column. These proteins also have specific characteristics that distinguish them from each other, in that, when the proteins are immobilized on nitrocellulose in a solid phase assay such as that disclosed herein, the 90 kD protein does not bind to AGE-modified ligands while the 60 kD protein does.
  • the preferred cells in this instance having receptors which are useful herein comprise mammalian mesangial cells; the preferred cellular components comprise cell membranes, and the cell proteins are derived from cell membranes and are selected from the group consisting of a 50 kD protein derived from MC membranes, a 40 kD protein derived from MC membranes, and a 30-35 kD protein derived from MC membranes, as well as mixtures thereof, having the reactivity which is described herein.
  • the NH 2 - terminal partial amino acid sequences of each of the proteins have been prepared and confirm that each protein is distinguishable from the other as well as to other known protein fractions as to sequence homology.
  • the NH 2 -terminal partial amino acid sequence for the 90 kD protein is presented below in FIGURE 11 and in Sequence ID No. 1, or SEQ ID NO:l, and comprises a single chain of 13 amino acids including two unidentified residues.
  • the partial amino acid sequence depicted in SEQ ID N0:1 is reproduced below, with X representing the unidentified residues.
  • the NH 2 -terminal partial amino acid sequence for the 60 kD protein is presented in FIGURE 12 and in Sequence ID No. 2, or SEQ ID NO:2, and comprises a single chain of 22 amino acids including two unidentified residues.
  • the partial amino acid sequence depicted in SEQ ID NO:2 is reproduced below, with X representing the unidentified residues.
  • the partial DNA sequence corresponding to the partial amino acid sequences of the proteins of the present invention or a portion thereof, or a degenerate variant of such partial DNA sequence may be prepared as a probe to screen for complementary sequences and genomic clones in the same or alternate species, such as humans.
  • the present invention extends to probes so prepared that may be provided for screening cDNA and genomic libraries for clones that may corrrespond to genes expressing the respective proteins.
  • the probes may be prepared with a variety of known vectors.
  • the present invention also includes the preparation of plasmids including such vectors.
  • the present invention also includes full proteins having the activities noted herein, and that display the partial amino acid seqences set forth and described above and with respect to SEQ ID NO:l and SEQ ID NO:2.
  • the full DNA sequence of the recombinant DNA molecule or cloned gene so determined may be operatively linked to an expression control sequence which may be introduced into an appropriate host.
  • the invention accordingly extends to unicellular hosts transformed with the cloned gene or recombinant DNA molecule comprising a DNA sequence encoding the 60kD and the 90kD protein, and more particularly, the complete DNA sequences determined from the partial sequences set forth above and in SEQ ID N0:1 and SEQ ID NO:2.
  • the receptors and/or the proteins may be prepared alone or in operative association with another molecule or pharmaceutical agent in a form suitable for administration for either diagnostic or therapeutic purposes.
  • the invention therefore extends to both diagnostic and pharmaceutical compositions including the receptors and/or the proteins, in combination with other diagnostic reagents in the former instance, and in combination with pharmaceutically acceptable carriers, and possibly, other therapeutic agents where coadministration is deemed appropriate or desirable.
  • the present receptors and the proteins play in the recognition and removal of AGEs and in tissue remodeling is as yet largely undefined, its participation in the elicitation of certain of these activities may be strongly inferred.
  • the receptors and the proteins are therefore believed to possess significant diagnostic and therapeutic capabilities in connection with conditions involving the presence and activity of advanced glycosylation endproducts.
  • the receptors and the proteins may be prepared by isolation and purification from cells known to bear or produce the receptor and/or its protein, such as rat liver cells, monocytes and peritoneal acrophage.
  • the cells or active fragments likely to participate in receptor protein synthesis or to have receptor protein associated therewith may be subjected to a series of known isolation techniques, such as for example elution of detergent-solubilized rat liver membrane proteins from an AGE-protein affinity matrix, whereupon the present receptor and/or the proteins may be recovered.
  • isolation techniques such as for example elution of detergent-solubilized rat liver membrane proteins from an AGE-protein affinity matrix, whereupon the present receptor and/or the proteins may be recovered.
  • alternate procedures for preparation of the receptor and/or the proteins are contemplated and the invention is not limited to the procedures set forth herein.
  • the present invention also extends to antibodies including polyclonal and monoclonal antibodies, to the receptor and the proteins that would find use in a variety of diagnostic and therapeutic applications.
  • the antibodies could be used to screen expression libraries to obtain the gene that encodes either the receptor or the proteins.
  • those antibodies that neutralize receptor protein activity could initially be employed in intact animals to better elucidate the biological role that the receptor and/or proteins plays.
  • Such antibodies could also participate in drug screening assays to identify alternative drugs or other agents that may exhibit the same activity as the receptor proteins.
  • Possible therapeutic applications of the receptor and/or the proteins would include administration in instances where it is desirable to. stimulate the removal of advanced glycosylation endproducts and to correspondingly aid in the treatment of ailments where excess concentrations of AGEs may cause or exacerbate other dysfunctions or pathologies, such as diabetes.
  • the present invention also includes various diagnostic and therapeutic utilities predicated on the structure and activities of the receptor and/or the proteins.
  • Diagnostic utilities include assays such as immunoassays with labeled quantities of the receptor proteins, antibodies, ligands and. binding partners thereto, receptor assays, and a drug screening assay to evaluate new drugs by their ability to promote or inhibit receptor protein production or activity, as desired.
  • the above assays could be used to detect the presence and activity of the receptor proteins or of invasive stimuli, pathology or injury the presence or absence of which would affect receptor protein production or activity.
  • the present invention also extends to therapeutic methods and corresponding pharmaceutical compositions based upon the receptor proteins, and materials having the same or an antagonistic activity thereto.
  • Therapeutic methods would be based on the promotion of the activities of the receptor proteins and would extend to the treatment of diseases or dysfunctions attributable to the absence of receptor protein activity, and the concomitant excess in concentrations of AGEs in the host or patient such as for example, diabetic neuropathy, renal failure, atherosclerosis, stroke, cataracts, diabetic retinopathy, and the like.
  • This method could be effected with the receptor, its proteins, their agonists or like drugs, or materials having a promotional effect on the production of the receptor proteins .in vivo.
  • compositions comprising effective amounts of the receptor, the receptor proteins, their agonists, antibodies, antagonists, or like drugs, etc. , and pharmaceutically acceptable carriers are also contemplated. Such compositions could be prepared for a variety of administrative protocols, including where appropriate, oral and parenteral administration. Exact dosage and dosing schedule would be determined by the skilled physician.
  • Diagnostic applications generally extend to a method for the measurement of protein aging both in plants and in animals, by assaying the presence, amount, location and effect of such advanced glycosylation endproducts.
  • Assays of plant matter and animal food samples will be able for example, to assess food spoilage and the degradation of other protein material of interest so affected, while the assays of animals, including body fluids such as blood, plasma and urine, tissue samples, and biomolecules such as DNA, that are capable of undergoing advanced glycosylation, will assist in the detection of pathology or other systemic dysfunction.
  • the methods comprise the performance of several competitive assay protocols, involving the analyte, a ligand and one or more binding partners to the advanced glycosylation endproducts of interest, where the binding partners are selected from the present receptor and/or the proteins.
  • the binding partners may be generally selected from the group consisting of rat liver cells as well as monocytes and macrophage having the present receptor and/or the proteins, cell components such as rat liver membranes, and the particular cell proteins set forth herein.
  • the cell proteins are selected from the group consisting of the 90 kD protein derived from rat liver membranes, the 60 kD protein derived from rat liver membranes, and mixtures thereof.
  • the ligands useful in the present invention are generally AGE derivatives that bind to AGE binding partners. These ligands may be detected either singly and directly, or in combination with a second detecting partner such as avidin.
  • Suitable ligands are selected from the reaction products of sugars such as glucose and glucose-6-phosphate with peptides, proteins and other bioche icals such as BSA, avidin, biotin, and enzymes such as alkaline phosphatase.
  • Other suitable ligands may include synthetic AGEs or the reaction of the sugars directly with carriers capable of undergoing advanced glycosylation. Carriers not so capable may have a synthetic AGE coupled to them.
  • Suitable carriers may comprise a material selected from carbohydrates, proteins, synthetic polypeptides, lipids, bio ⁇ compatible natural and synthetic resins, antigens, and mixtures thereof.
  • standard assays based on either cell components or the cell proteins themselves and employing extract formats may be used.
  • Each assay is capable of being based on enzyme linked and/or radiolabeled AGEs and their binding partners, including the AGE receptors disclosed herein.
  • the broad format of assay protocols possible with the present invention extends to assays wherein no label is needed for AGE detection.
  • one of the formats contemplates the use of a bound protein-specific AGE receptor. In such instance, the analyte suspected of containing the advanced glycosylation endproducts under examination would need only to be added to the receptor, and the bound analyte could then be easily detected by a change in the property of the binding partner, such as by changes in the receptor.
  • the assays of the invention may follow formats wherein either the ligand or the binding partner, be it a receptor or an antibody, are bound.
  • the assays include the use of labels which may be selected from radioactive elements, enzymes and chemicals that fluoresce.
  • compositions for use in therapeutic methods which comprise or are based upon the receptor and/or the proteins or their binding partner(s), or upon agents or drugs that control the production and/or activities of the receptor and/or the proteins.
  • FIGURE 1 is a graph depicting the relative binding and uptake of red blood cells modified with various agents, and illustrating a primary aspect of the present invention.
  • FIGURE 2 is a graph illustrating an assay in accordance with the present invention by the competitive inhibition in red blood cell binding caused by the introduction into a sample of an agent capable of stimulating red blood cells to increase their activity of recognition and removal of advanced glycosylation endproducts.
  • FIGURE 3 is a bar graph illustrating the comparative uptake and degradation of advanced glycosylation endproducts by mouse macrophages exposed to various stimulator compounds.
  • FIGURE 4 is a bar graph illustrating data similar to that set forth in FIGURE 3, with respect to one day old human monocytes.
  • FIGURE 5(A) In vivo tissue distribution of 125 I-AGE-RSA.
  • I25 I-AGE-rat serum albumin (AGE-RSA) (filled and striped bars) or I25 I-native RSA (shaded bars) were administered i.v. to normal rats. At 10 min the animals were sacrificed, and the organs and tissues were removed and counted for radioactivity. Whole organ counts were corrected for blood-associated counts as described in Methods.
  • FIGURE 5(B) Specific competition of 125 I-AGE-RSA uptake in rat liver, spleen, lung and kidney. Immediately prior to receiving radio-labeled ligand, rats were injected with excess non-labeled AGE-RSA (5 mg, i.v.).
  • incorporated radioactivity was determined in blood and tissues, and compared according to a Tissue-to-Blood Isotope Ratio (TBIR) formula as described in text. Closed and striped bars: 125 I-AGE-RSA (50 ⁇ g) alone. Open bars: 1S I-AGE- RSA (50 ⁇ g) in the presence of excess non-labeled AGE-RSA. Data are expressed as mean ⁇ SEM of three independent measurements performed in five animals per group.
  • FIGURE 6 depicts several graphs of an AGE-binding activity assay:
  • AGE-BSA AGE-albumin
  • AGE-RNAse AGE-ribonuclease
  • AGE-collagen I FFI-BSA
  • formaldehyde-treated albumin f-alb
  • glucosamide BSA acetyl-LDL (act-LDL)
  • Data are expressed as the amount of 125 I-AGE-BSA (cpm X 10 -3 ) retained on duplicate blots.
  • FIGURE 7 shows the purification of rat liver AGE-binding proteins.
  • Detergent-solubilized membrane proteins were fractionated by successive PEI-cellulose, DEAE-cellulose, and BSA-Sepharose 4B column chromatography, as described in Methods. The flow-through from the BSA-Sepharose column was then applied to an AGE-BSA-Sepharose 4B column. This column was washed and bound proteins were eluted by the addition of high salt buffer. Each fraction was concentrated and analyzed for AGE-binding activity using the binding assay described in Figure 6. Open circles: total binding activity; closed circles: non-specific activity. Inset: SDS-PAGE analysis of fraction #8 (mercaptoethanol reduced) , and stained with Coommassie Blue.
  • FIGURE 8 (A) Ligand blot analysis of rat liver membrane proteins. Aliquots (15 ⁇ g each) of detergent-solubilized membrane proteins were electrophoresed through 8-16% acrylamide gradient gel under non-reducing conditions and eletro-transferred onto nitrocellulose filters. Using 125 I-AGE- BSA (50 nM, 8.0 X 10 5 cpm/ng) as probe, specific binding was determined in the presence of 0, 25, or 150-fold excess non- labeled AGE-BSA using autoradiographic detection. Migration of molecular weight standards is shown at left. (B)
  • FIGURE 9 Demonstration by flow cytometry of expression of p60 and p90 AGE-binding proteins rat monocytes and macrophages.
  • Peripheral blood monocytes (A-D) and peritoneal resident macrophages (E and F) were treated with biotinylated anti-p60 alone (A and E) , biotinylated anti-p90 alone (B and F) , biotinylated anti-p60 + 20-fold excess unconjugated anti- p90 (C) , biotinylated anti-p90 + 20-fold excess unconjugated anti-p60 (D) , followed by FITC-avidin and analyzed by FACSCAN.
  • Arrow 1 Fluorescence of cells treated with FITC-avidin in the absence of either anti-p60 or anti-p90 (dotted line) .
  • Arrow 2 Fluorescence of cells treated with FITC-avidin subsequent to treatment with biotinylated chicken IgG (isotypic control) .
  • Arrow 3 Fluorescence of cells treated with FITC-avidin subsequent to treatment of cells with biotinylated anti-p60 (A,C,E) and anti-p90 (B,D,F).
  • FIGURE 10 Inhibition of l25 I-AGE-BSA binding (A) and 125 I-FFI- BSA binding (B) on rat macrophage cell surface by anti-p60 and anti-p90 antibodies.
  • Rat peritoneal resident macrophages were collected by peritoneal lavage and purified, then incubated with the indicated radio-labeled ligand in the presence or absence of a 10-fold excess of non-labeled ligand or in the presence of antibodies p60 or p90-specific at the indicated dilutions. Both antibodies were used alone (undiluted: 2 ⁇ g/200 ⁇ l) or in combination (at 1:10 dilution). Data are expressed as % of maximal control binding (defined as the amount of I25 I-ligand bound to the cell surface in the presence of 10% FBS) and represent the mean of duplicate experiments.
  • FIGURE 11 depicts the NH 2 -terminal partial amino acid sequence prepared by blotting a quantity of gel-purified rat liver membrane protein having a molecular mass of about 90 kD (p90) onto Immobilon membranes.
  • the amino acids are numbered from 1 to 13. This sequence is identically depicted in the SEQUENCE LISTING presented later on herein, in accordance with 37 C.F.R. 1.821-825, enacted October 1, 1990, and is cumulatively and alternately referred to as SEQ ID NO:l.
  • FIGURE 12 depicts the NH 2 -terminal partial amino acid sequence prepared by blotting a quantity of gel-purified rat liver membrane protein having a molecular mass of about 60 kD (p60) onto Immobilon membranes.
  • the amino acids are numbered from 1 to 22.
  • This sequence is identically depicted in the SEQUENCE LISTING presented later on herein, in accordance with 37 C.F.R. 1.821-825, enacted October 1, 1990, and is cumulatively and alternately referred to as SEQ ID NO:2.
  • FIGURE 13 Binding of '"i-AGE-BSA to human fA * ⁇ and rat fBI MC membranes.
  • 10 ⁇ g of solubilized membrane protein from human and rat mesangial cells were dot-blotted onto nitrocellulose filters, which were then incubated with various concentrations of I5 I-AGE-BSA in the presence and absence of 100-fold excess unlabeled AGE-BSA.
  • Specific binding was obtained by subtracting the nonspecific binding from the total binding.
  • FIGURE 14 Competitive inhibition of 125 I-AGE-BSA binding to human (A) and rat (B) MC membranes. 10 ⁇ g of solubilized membrane protein from human and rat MCs were dot-blotted onto nitrocellulose filters. The filters were incubated with 50 nM ,25 I-AGE-BSA for 2 hours at 4°C. Competition experiments were performed in parallel experiments in which the radioligand was incubated with 100-molar excess of an unlabeled protein. Data shown are the average of duplicate determinations, and are expressed as the % maximal binding. Maximal binding was defined as the amount of ,25 I-AGE-BSA bound in the presence of 100-molar excess cold BSA. Competitors used: (a) BSA, (b)
  • AGE-BSA (c) NaBH 4 -reduced AGE-BSA, (d) FFI-BSA, (e) AGE-RNAse, (f) RNAse, (g) Collagen I, (h) AGE-collagen I.
  • 125 I-AGE-BSA for 4 hours at 37°C.
  • the amount of cell-associate 12S I-AGE-BSA (uptake) , and the amount of trichloroacetic acid-soluble counts in the medium (degradation) were determined in triplicate wells.
  • FIGURE 16 Ligand blot analysis of enriched human MC membranes. 10 ⁇ g of solubilized membrane protein were electrophoresed on a nonreducing SDS/polyacrylamide gel (10%) . The proteins on the gel were electroblotted onto nitrocellulose membrane and probed with I25 I-AGE-BSA in the presence of 100-fold excess of either BSA (lane a) or AGE-BSA (lane b) . The analysis presented is one of four identical experiments.
  • FIGURE 17 Effects of AGE-matrices on r 3 H1thymidine incorporation by MCs.
  • Rat MCs were plated onto various matrices (10 ⁇ g/ml) , as described: (a) Fibronectin, (b) AGE- Fibronectin, (c) Collagen I, (d) AGE-Collagen I, (e) Laminin, (f) AGE-Laminin.
  • the results are expressed as the means ⁇ SEM of 6 experiments and are expressed as the % of [ 3 H] hymidine incorporated relative to the control value, with control representing [ 3 H]thymidine incorporated by cells plated on plastic.
  • FIGURE 18 Effect of AGE- atrices on fibronectin synthesis by MCs. Human MCs were plated onto either unmodified or
  • AGE-modified matrices and labeled with 35S-methionine and cysteine, as described.
  • the amount of fibronectin released into the medium (A) , and incorporated into the matrices (B) was determined by i munoprecipitation.
  • the fibronectin bands on the gel were excised and counted for radioactivity.
  • the values shown are expressed as the % increase in fibronectin produced by cells plated on the AGE-matrices relative to that produced by cells plated on control unmodified matrices. The values show cpm/well and represent the means ⁇ SEM from 4 experiments. a) Fibronectin, b) Polylysine, c) Collagen I.
  • amino acid residues described herein are preferred to be in the "L" isomeric form.
  • residues in the "D" isomeric form can be substituted for any L-amino acid residue,, as long as the desired fuctional property of immunoglobulin- binding is retained by the polypeptide.
  • NH2 refers to the free amino group present at the amino terminus of a polypeptide.
  • COOH refers to the free carboxy group present at the carboxy terminus of a polypeptide.
  • amino-acid residue sequences are represented herein by formulae whose left and right orientation is in the conventional direction of amino-terminus to carboxy-terminus. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or more amino-acid residues.
  • the above Table is presented to correlate the three-letter and one-letter notations which may appear alternately herein.
  • receptor and “receptor protein(s)” include both the singular and plural and contemplates the existence of a single receptor structure comprised as all or part thereof, of the individual proteins defined herein, or a plurality of receptor structures respectively constituted in whole or in part by individual of said proteins. This definition is therefore to be explicitly distinguished from the definition that may be inferred from the term as it appears in the manuscript by Yang et al. from which the present application is drawn in part.
  • an “antibody” is any immunoglobulin, including antibodies and fragments thereof, such as Fab, F(ab') 2 or dAb, that binds a specific epitope.
  • the term encompasses, inter alia, polyclonal, monoclonal, and chimeric antibodies, the last mentioned described in further detail in U.S. Patent Nos. 4,816,397 and 4,816,567.
  • An antibody preparation is reactive for a particular antigen when at least a portion of the individual immunoglobulin molecules in the preparation recognize (i.e., bind to) the antigen.
  • An antibody preparation is non-reactive for an antigen when binding of the individual immunoglobulin molecules in the preparation to tlie antigen is not detectable by commonly used methods.
  • the present invention relates to receptors including proteins as defined herein that are derived from either rat liver membranes, as well as monocytes and peritoneal macrophage, or from mesangial cells, and that recognize and bind advanced glycosylation endproducts.
  • the receptors possess at least one of the following characteristics:
  • They comprise at least one protein selected from the group consisting of a protein having a molecular mass of about 90 kD, a protein having a molecular mass of about 60 kD, a protein having a molecular mass of about 50 kD, a protein having a molecular mass of about 40 kD, and a protein having a molecular mass ranging from about 30 to about 35 kD, as determined by migration on SDS-PAGE.
  • the receptors are derived from rat liver membrane cells and possess the following characteristics:
  • they comprise at least two proteins, the first of said proteins having a molecular mass of about 90 kD and the second of said proteins having a molecular mass of about 60 kD as determined by their migration on SDS-PAGE.
  • the receptors are derived from mesangial cells and possess the following characteristics: A. they recognize and bind with the ligands AGE-BSA, AGE-RNAse and AGE-collagen I in a saturable fashion, having a binding affinity of 2.0 ⁇ 0.4 x 10 6 M *1 (500nM) ; B. they recognize and bind to AGE-BSA which has been reduced with NaBH 4 ;
  • they comprise at least one protein selected from the group consisting of a first protein having a molecular mass of about 50kD, a second protein having a molecular mass of about
  • the individual proteins listed above have certain common characteristics, to the extent that the proteins derived from rat liver cells are also expressed on both rat monocytes and macrophages, and both proteins copurify from elutions based, respectively, on an AGE ligand affinity column, an anion exchange column, and a hydroxylapatite column. These proteins also have specific characteristics that distinguish them from each other, in that, when the proteins are immobilized on nitrocellulose in a solid phase assay such as that disclosed herein, the 90 kD protein does not bind to AGE-modified ligands while the 60 kD protein does.
  • NH 2 -terminal partial amino acid sequences of each of the proteins of the liver-derived receptors have been prepared and confirm that each protein bears no homology with the other as well as with other known protein fractions.
  • the NH 2 -terminal partial amino acid sequence for the 90 kD protein is presented below and in SEQ ID NO:l, and comprises a single chain of 13 amino acids including two unidentified residues represented by "X".
  • the partial DNA sequence corresponding to the partial amino acid sequences of the proteins of the present invention or a portion thereof may be prepared as a probe to screen for complementary sequences and genomic clones in the same or alternate species, such as humans.
  • the present invention extends to probes so prepared that may be provided for screening cDNA and genomic libraries for clones that may corrrespond to genes expressing the respective proteins.
  • the probes may be prepared with a variety of known vectors, such as phage ⁇ vectors.
  • the present invention also includes the preparation of plasmids including such vectors.
  • the present invention also includes full proteins having the activities noted herein, and that display the partial amino acid seqences set forth and described above and with respect to SEQ ID NO:l and SEQ ID NO:2.
  • mesangial cells are contained in the mammalian kidneys and function in conjunction with the glomeruli to regulate the glomerular filtration rate, thus affecting glomerular flow.
  • AGE- modified proteins accumulate in the mesangial matrix and bind to these receptors, MC proliferation, synthesis, metabolism and physiology are modified. For example, the proliferation of MCs is reduced when AGEs have reacted with MC receptors as compared to MCs which have not been exposed to AGEs.
  • the MC receptor complex for AGEs is comprised of three distinct proteins, 50kD, 40kD and 30-35 kD. This was demonstrated using a ligand blotting assay of MC membrane extracts, the procedure of which is described below. The results are shown in FIGURE 16.
  • the MC AGE receptor was further characterized with respect to its binding affinity, using a series of assays. It was determined that the MC membrane AGE receptors bind AGEs in a saturable fashion. (See FIGURE 13.) When MC membrane extracts were exposed to increasing levels of AGEs, specific binding plateaued, even as AGE levels were increased. Half- maximal binding occurred at about a 150nM concentration of AGE-BSA. This was consistent between rat and human MC membrane extracts. The number of AGE molecules bound per cell was in the range of 3.0 ⁇ 0.25 x 10 5 molecules per cell. The binding affinity constant was 2.0 ⁇ 0.40 x 10 6 M" 1 (kD - 500nM) .
  • the MC receptor binding affinity was further evaluated, and it was determined that the MC receptor for AGE- odified proteins is reactive with AGE-modified proteins and non- reactive with proteins in unmodified form.
  • Specific binding to the receptors was defined as the difference between total binding (radioligand incubated with membrane protein alone) and non-specific binding (cell incubated with radiolabelled ligand plus 100 fold excess of unlabelled ligand) .
  • the AGE-modified protein receptors were further characterized with respect to binding for AGE-BSA in reduced form.
  • AGE-BSA was reduced with NaBH 4 to glucitolysine and further evaluated.
  • the reduced AGE-BSA effectively competed with radiolabelled AGE-BSA for binding to MC membrane extracts (FIGURE 14) .
  • the characteristics of the MC AGE-modified protein receptor were evaluated to determine the number of proteins involved and their molecular weight. It was determined that three distinct membrane proteins are present in the receptor complex, 50kD, 40kD and 30-35 Kd, using a ligand blot analysis.
  • FIGURE 16 shows three prominent AGE binding proteins. Binding of radiolabelled AGE to these membrane proteins was specific. Again, excess unlabelled AGE-BSA could inhibit labelled AGE-binding for both rat and human MCs, whereas BSA did not inhibit labelled AGE binding.
  • AGE- modified MCs were incubated with and without AGE-modified proteins in the presence of labelled thymidine. (Thymidine is taken up during DNA synthesis) . The results are shown in FIGURE 17.
  • AGE- modified MCs showed a decrease in label uptake over MCs not exposed to AGEs.
  • MC proliferation was also evaluated in the presence of matrix proteins, fibronectin, collagen I and laminin, comparing MC growth on plates coated with these matrix proteins to that which occurs in the presence of these matrix proteins in AGE modified form.
  • the results are shown in FIGURE 17.
  • Labelled thymidine uptake was used as the measure of MC proliferation. When used in a concentration of 10 mg/ml, the uptake of labelled thymidine uptake was consistently reduced in the presence of AGE-modified matrix proteins, approximately to the level of incorporation in MCs plated on plastic.
  • Degradation of AGEs was determined by measuring the amount of label present in the aspirated medium.
  • AGEs The effect of AGEs on fibronectin production in MCs was also evaluated.
  • Mesangial cells were grown on AGE-modified or unmodified collagen I, fibronectin and polylysine media.
  • the amount of fibronectin released into the medium (or incorporated into the matrix) was determined by immunoprecipitation with IgG purified anti-human fibronectin antibodies. The results are shown in FIGURE 18, showing an increase in the synthesis of fibronectin in the presence of AGE- modified proteins.
  • the mesangial cells receptors for AGE- modified proteins can further be characterized by comparing said receptors to other known AGE- receptors, such as on macrophage and endothelial cells.
  • AGEs have been shown to bind to specific receptors on murine and human monocyte/macrophages, as well as on bovine and human endothelial cells. Since AGEs form progressively over time, the function of AGE receptors is believed to include signalling cells to promote turnover of aging tissue. Under normal conditions, the removal of AGE- modified proteins occurs at a rate which keeps up with production, thereby preventing accumulation. In diabetes, excessive AGE formation in the presence of elevated glucose levels results in a net increase of AGEs on most structural tisue proteins.
  • Macrophages are induced to release the cytokines catechin/tumor necrosis factor (TNF) , interleukin-1 (IL-1) , platelet derived growth factor (PDGF) ,__ and insulin-like growth factor (ILGF) .
  • TNF catechin/tumor necrosis factor
  • IL-1 interleukin-1
  • PDGF platelet derived growth factor
  • ILGF insulin-like growth factor
  • Endothelial cell AGE receptors induce several changes in EC functionwhich are characteristic in diabetes, such as increased EC permeability and procoagulant properties.
  • the macrophage AGE receptors recognize the model AGE, FFI-BSA; in contrast, endothelial cell AGE receptors do not recognize the AGE- FFI-BSA.
  • the ability of MCs to slowly internalize and degrade AGE- modified proteins points to a contribguting role for MCs in the turnover and remodeling of senescent AGE- modified mesangial matrix proteins.
  • the efficiencywith which MCs ingest and degrade AGE-BSA is approximately 10% of that which has been reported for the macrophage.
  • the AGE receptors on MCs, macrophage cells and endothelial cells all recognize AGEs to a degree, there are other differences.
  • the Kds for the receptors are different.
  • the Kd for macrophage and endothelial cell AGE receptors is about 70-100nM; the Kd for MC AGE receptors is about 500nM.
  • the receptor and/or the proteins may be prepared by isolation and purification from cells known to bear or produce the receptor and/or the proteins, such as rat liver cells, monocytes and peritoneal macrophage.
  • the cells or active fragments likely to participate in receptor protein synthesis or to have receptor protein associated therewith may be subjected to a series of known isolation techniques, such as for example elution of detergent-solubilized rat liver membrane proteins from an AGE-protein affinity matrix, whereupon the present receptor and/or the proteins may be recovered.
  • isolation techniques such as for example elution of detergent-solubilized rat liver membrane proteins from an AGE-protein affinity matrix, whereupon the present receptor and/or the proteins may be recovered.
  • a specific protocol is set forth by way of illustration in Example III, later on herein.
  • the present invention naturally contemplates alternate means for preparation of the receptor and/or the proteins, including stimulation of receptor producer cells with promoters of receptor synthesis followed by the isolation and recovery of the receptor as indicated above, as well as chemical synthesis, and the invention is accordingly intended to cover such alternate preparations within its scope.
  • the present invention also extends to antibodies including polyclonal and monoclonal antibodies, to the receptor and the proteins that would find use in a variety of diagnostic and therapeutic applications.
  • the antibodies could be used to screen expression libraries to obtain the gene that encodes either the receptor or the proteins.
  • those antibodies that neutralize receptor protein activity could initially be employed in intact animals to better elucidate the biological role that the receptor and/or the proteins plays.
  • Such antibodies could also participate in drug screening assays to identify alternative drugs or other agents that may exhibit the same activity as the receptor proteins.
  • Both polyclonal and monoclonal antibodies to the receptor are contemplated, the latter capable of preparation by well known techniques such as the hybridoma technique, utilizing, for example, fused mouse spleen lymphocytes and myeloma cells.
  • Immortal, antibody-producing cell lines can also be created by techniques other than fusion, such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with
  • Epstein-Barr virus Epstein-Barr virus.
  • Specific avian polyclonal antibodies were raised herein and are set forth in Example III. Naturally, these antibodies are merely illustrative of antibody preparations that may be made in accordance with the present invention.
  • the present invention contemplates both diagnostic and therapeutic applications for these agents. Accordingly, the receptor and/or the proteins may be prepared for use in a variety of diagnostic methods, set forth in detail hereinafter, and may be labeled or unlabeled as appropriate. Likewise, the receptor and/or the proteins may be prepared for administration in various scenarios for therapeutic purposes, in most instances to assist in reducing the concentration of AGEs in vivo.
  • the receptor and/or the proteins may be prepared in a therapeutically effective concentration as a pharmaceutical composition with a pharmaceutically acceptable carrier.
  • Other compatible pharmaceutical agents may possibly be included, so that for example certain agents may be simultaneously coadministered.
  • the receptor and/or the proteins may be associated with or expressed by a compatible cellular colony, and the resulting cellular mass may then be treated as a therapeutic agent and administered to a patient in accordance with a predetermined protocol.
  • Numerous therapeutic formulations are possible and the present invention contemplates all such variations within its scope.
  • a variety of administrative techniques may be utilized, among them topical applications as in ointments or on surgical and other topical appliances such as, surgical sponges, bandages, gauze pads, and the like.
  • such compositions may be administered by parenteral techniques such as subcutaneous, intravenous and intraperitoneal injections, catheterizations and the like.
  • the administration of the present receptor and/or the proteins comprises an effective therapeutic method.
  • Such conditions as diabetic nephropathy, renal failure and the like may be treated and/or averted by the practice of the therapeutic methods of the present invention.
  • Average quantities of the active agent may vary and in particular should be based upon the recommendations and prescription of a qualified physician or veterinarian, with an exemplary dosage regimen extending to up to about 25 mg/kg/day.
  • the present invention also relates to a variety of diagnostic applications, including methods for the measurement of the presence and amount of advanced glycosylation endproducts in both plants and animals, including humans.
  • the methods comprise assays involving in addition to the analyte, one or more binding partners of the advanced glycosylation endproducts, and one or more ligands.
  • the present assay method broadly comprises the steps of: A. preparing at least one biological sample suspected of containing said advanced glycosylation endproducts;
  • binding partner includes or is selected from the present receptor, the receptor proteins, and mixtures;
  • Step D placing the labeled material from Step C in contact with a material selected from the group consisting of the material from Step C that is not labeled;
  • Step D examining the resulting sample of Step D for the extent of binding of said labeled material to said unlabeled material.
  • Suitable analytes may be selected from plant matter, blood, plasma, urine, cerebrospinal fluid, lymphatic fluid, and tissue; and the compounds FFI and AFGP, individually and bound to carrier proteins such as the protein albumin.
  • the analyte may also comprise a synthetically derived advanced glycosylation endproduct which is prepared, for example, by the reaction of a protein or other macromolecule with a sugar such as glucose, glucose-6-phosphate, or others. This reaction product could be used alone or could be combined with a carrier in the same fashion as the FFI-albumin complex.
  • the carrier may be selected from the group consisting of carbohydrates, proteins, synthetic polypeptides, lipids, bio ⁇ compatible natural and synthetic resins, antigens and mixtures thereof.
  • the present invention seeks by means of the present receptor to diagnose both the degradative effects of advanced glycosylation of proteins in plants and the like, and the adverse effects of the buildup of advanced glycosylation endproducts in animals.
  • Such conditions as age- or diabetes- related hardening of the arteries, skin wrinkling, arterial blockage, and diabetic, retinal and renal damage in animals all result from the excessive buildup or trapping that occurs as advanced glycosylation endproducts increase in quantity. Therefore, the diagnostic method of the present invention seeks to avert pathologies caused at least in part by the accumulation of advanced glycosylation endproducts in the body by monitoring the amount and location of such AGEs.
  • the assays of the present invention are particularly suited to design and performance around this activity.
  • the present receptor or and/or the proteins and/or cellular material bearing the receptor may be combined with the analyte and the ligand and the binding activity of either or both the ligand or the analyte to the receptor may then be measured to determine the extent and presence of the advanced glycosylation endproduct of interest.
  • the differences in affinity between the components of the assay serves to identify the presence and amount of the AGE.
  • the present invention also relates to a method for detecting the presence of stimulated, spontaneous, or idiopathic pathological states in mammals, by measuring the corresponding presence of advanced glycosylation endproducts. More particularly, the activity of AGEs may be followed directly by assay techniques such as those discussed herein, through the use of an appropriately labeled quantity of at least one of the binding partners to AGEs as set forth herein. Alternately, AGEs can be used to raise binding partners or antagonists that could in turn, be labeled and introduced into a medium to test for the presence and amount of AGEs therein. and to thereby assess the state of the host from which the medium was drawn.
  • both AGE receptors and any binding partners thereto are capable of use in connection with various diagnostic techniques, including immunoassays, such as a radioimmunoassay, using for example, a receptor or other ligand to an AGE that may either be unlabeled or if labeled, then by either radioactive addition, reduction with sodium borohydride, or radioiodination.
  • immunoassays such as a radioimmunoassay
  • a control quantity of a binding partner to advanced glycosylation endproducts may be prepared and optionally labeled, such as with an enzyme, a compound that fluoresces and/or a radioactive element, and may then be introduced into a tissue or fluid sample of a mammal believed to be undergoing invasion. After the labeled material or its binding partner(s) has had an opportunity to react with sites within the sample, the resulting mass may be examined by known techniques, which may vary with the nature of the label attached.
  • the presence of AGE activity in animals and plants can be ascertained in general by immunological procedures are which utilize either a binding partner to the advanced glycosylation endproduct or a ligand thereto, optionally labeled with a detectable label, and further optionally including an antibody Ab, labeled with a detectable label, an antibody Ab 2 labeled with a detectable label, or a chemical conjugate with a binding partner to the advanced glycosylation endproduct labeled with a detectable label.
  • the procedures may be summarized by the following equations wherein the asterisk indicates that the particle is labeled, and "BP" in this instance stands for all binding partners of advanced glycosylation endproduct(s) under examination:
  • a further alternate diagnostic procedure employs multiple labeled compounds in a single solution for simultaneous radioimmune assay.
  • a composition may be prepared with two or more analytes in a coordinated compound having the formula: radioisotope-chelator-analyte.
  • the advanced glycoslation endproduct forms complexes with one or more binding partners and one member of the complex may be labeled with a detectable label.
  • a complex has formed and, if desired, the amount thereof, can be determined by the known applicable detection methods.
  • Ab 2 With reference to the use of an AGE antibody as a binding partner, it will be seen from the above that a characteristic property of Ab 2 is that it will react with Ab,. This is because Ab, raised in one mammalian species has been used in another species as an antigen to raise the antibody Ab 2 . For example, Ab 2 may be raised in goats using rabbit antibodies as antigens. Ab 2 therefore would be anti-rabbit antibody raised in goats. Where used and for purposes of this description, Ab, will be referred to as a primary or anti-advanced glycosylation endproduct antibody, and Ab 2 will be referred to as a secondary or anti-Ab, antibody.
  • the labels most commonly employed for these studies are radioactive elements, enzymes, chemicals which fluoresce when exposed to ultraviolet light, and others.
  • Suitable radioactive elements may be selected from the group consisting of 3 H, 14 C, 32 P, 35 S, 36 C1, 5, Cr, 57 Co, 58 Co, 59 Fe, " ⁇ , 12S I, I3I I, and 186 Re.
  • a radioactive label such is prepared with one of the above isotopes is used, known currently available counting procedures may be utilized.
  • detection may be accomplished by any of the presently utilized colorimetric, spectrophotometric, fluorospectro-photometric, thermometric, amperometric or gasometric techniques known in the art.
  • the enzyme may be conjugated to the advanced glycosylation endproducts, their binding partners or carrier molecules by reaction with bridging molecules such as carbodiimides, diisocyanates, glutaraldehyde and the like.
  • the enzymes themselves may be modified into advanced glycosylation endproducts by reaction with sugars as set forth herein.
  • peroxidase peroxidase
  • ⁇ -glucuronidase peroxidase
  • ⁇ -D-glucosidase ⁇ -D-galactosidase
  • urease glucose oxidase plus peroxidase
  • hexokinase plus GPDase RNAse
  • glucose oxidase plus alkaline phosphatase NAD oxidoreductase plus luciferase
  • phosphofructokinase plus phosphoenol pyruvate carboxylase
  • aspartate aminotransferase plus phosphoenol pyruvate decarboxylase and alkaline phosphatase.
  • U.S. Patent Nos. 3,654,090; 3,850,752; and 4,016,043 are referred to by way of example for their disclosure of alternative labeling material and methods.
  • a number of fluorescent materials are known and can be utilized as labels. These include, for example, fluorescein, rhodamine and auramine.
  • a particular detecting material is anti-rabbit antibody prepared in goats and conjugated with fluorescein through an isothiocyanate.
  • the present invention includes assay systems that may be prepared in the form of test kits for the quantitative analysis of the extent of the presence of advanced glycosylation endproducts.
  • the system or test kit may comprise a labeled component prepared by one of the radioactive and/or enzymatic techniques discussed herein, coupling a label to a binding partner to the advanced glycosylation endproduct such as a receptor or ligand as listed herein; and one or more additional immunochemical reagents, at least one of which is a free or immobilized ligand, capable either of binding with the labeled component, its binding partner, one of the components to be determined or their binding partner(s) .
  • kits suitable for use by a medical specialist may be prepared to determine the presence or absence of advanced glycosylation endproducts.
  • one class of such kits will contain at least labeled AGE, or its binding partner as stated above, and directions, of course, depending upon the method selected, e.g., "competitive", “sandwich”, “DASP” and the like.
  • the kits may also contain peripheral reagents such as buffers, stabilizers, etc.
  • a first assay format contemplates a bound receptor to which are added the ligand and the analyte. The resulting substrate is then washed after which detection proceeds by the measurement of the amount of ligand bound to the receptor.
  • a second format employs a bound ligand to which the receptor and the analyte are added. Both of the first two formats are based on a competitive reaction with the analyte, while a third format comprises a direct binding reaction between the analyte and a bound receptor. In this format a bound receptor-specific carrier or substrate is used. The analyte is first added after which the receptor is added, the substrate washed, and the amount of receptor bound to the substrate is measured.
  • the present invention includes the following protocol within its scope:
  • a method for determining the amount of advanced glycosylation endproducts in an analyte comprising:
  • A providing a sample of monocytes bearing the present receptor protein(s); B. inoculating said sample with a known advanced glycosylation endproduct bound to a whole cell;
  • Step C counting the whole cells of Step B that are bound to and/or internalized by said sample.
  • test kit may be prepared for the demonstration of the presence and activity of AGEs, comprising:
  • the diagnostic test kit may comprise:
  • test kit may comprise:
  • RBCs human red blood cells
  • a quantity of RBCs were opsonized by incubation with an appropriate antiserum.
  • a further quantity was bound to the advanced glycosylation endproduct FFI by a carbodiimide bond, and additional RBCs were separately glycosylated by reactions with glucose, glucose-6-phosphate, xylose and arabinose, respectively.
  • AGE-BSA and human monocytes were prepared. Phagocytosis assays proceeded by the incubation of the RBCs with the monocyte cultures followed by fixation of the sample wells and lastly counting under 4Ox phase microscopy.
  • mice were washed at least four times to remove unbound isotope. Twelve Balb/c mice were then injected intravenously with 200 ⁇ l RBC suspension. Each sample was administered in three Balb/c mice. At appropriate time intervals the mice were bled (0.2 ml) and radioactivity levels were measured by counting.
  • This example comprises a series of experiments that were initially performed to measure the ability of agents to stimulate phagocytic cells to stimulate uptake and degradation of endproducts (AGEs) , and thereby further confirmed the hypothesis that this activity is receptor-mediated.
  • AGEs endproducts
  • FFI-HA was prepared as described and quantities were bound to both human and bovine albumin.
  • a water soluble carbodiimide was used to attach the acid moiety of the FFI-HA to an amino group on the protein. After preparation, the conjugate was purified and then used in vitro to stimulate macrophages, by incubation for from 4 to 24 hours.
  • the AGEs that were to be observed for uptake and degradation were appropriately radiolabeled so that they could be traced. Thereafter, the stimulated macrophages were tested by exposure to the radiolabeled AGEs following exposure to various agents to measure the effect that these agents had on the ability of the macrophages to take up and degrade the labeled AGEs.
  • the above procedures conform to the protocol employed by Vlassara et al., supra. and confirmed that a competitive assay based on a cellular receptor for AGEs is feasible.
  • monocyte or macrophage cells can also be stimulated by AGE-carrier molecules which result in cells with enhanced ability to bind, internalize and degrade other AGE-molecules.
  • AGE-carrier molecules are made, for example, from the reaction of glucose or glucose-6-phosphate with albumin. After purification of the reaction product, the AGE-albumin uptake of AGE-macromolecules demonstrated as in (A) above.
  • AGE-BSA prepared from the incubation of glucose- 6-phosphate with albumin for 6-8 weeks
  • 0.1 mg/ml demostrates a stimulatory effect on AGE-BSA uptake by human monocytes ( Figure 4, bar AA) , and shows a slight stimulation at higher concentrations (bars BB and CC) . This observation further supports the role of these ligands in conjunction with cellular receptors and point to the application of these agents in a competitive AGE assay protocol.
  • the following example discloses the purification from rat liver, and partial amino acid sequencing, of two membrane proteins of approximately 60 and 90 kD, respectively, that bind AGE-modified proteins. Both of the proteins presented are expressed on the surface of rat monocytes and resident peritoneal macrophages, suggesting a relationship to the AGE- receptor system earlier identified on these cells. The proteins are believed to be involved in tissue repair and remodelling.
  • Bovine serum albumin (BSA) (Fraction 1)
  • Triton X-114 and Triton X-100 were purchased from Boehringer Mannheim Biochemicals (Indianapolis, IN) .
  • Sodium 125 iodide was obtained from New England Nuclear (Boston, MA) .
  • Nitrocellulose membranes were from Schliecher & Schuell (Keene, NH) .
  • CNBr-activated Sepharose 4B was purchased from Pierce (Rockford, IL) .
  • LDL and acetyl-LDL were the generous gift of Dr. David Via (Baylor College of Medicine, Houston, TX) .
  • AGE-BSA AGE-BSA
  • AGE-RSA AGE-ribonuclease
  • AGE-collagen I AGE-collagen I
  • each protein solution 25 mg/ml was incubated with either 0.5 M glucose or glucose-6-phosphate in 100 mM phosphate buffer (pH 7.4) at 37°C for six weeks under sterile conditions, and then low molecular weight reactants were removed by dialysis against phosphate buffered saline (PBS; 20 mM sodium phosphate buffer containing 0.15 M NaCl, pH 7.4).
  • PBS phosphate buffered saline
  • FFI-HA was coupled to BSA with the water-soluble carbodiimide, EDAC, as described previously. Characteristic fluorescence of the AGE-proteins was observed at 450 nm upon excitation at 390 nm.
  • Formaldehyde-modified BSA was prepared as described, by incubating BSA in 0.1 M sodium carbonate buffer (pH 10) with 0.33 M formaldehyde at 37°C for 5 hours, followed by extensive dialysis against PBS. All protein concentrations were determined by the method of Bradford.
  • Protein and AGE-protein preparations were radio ⁇ labeled with [ I25 I] by the Iodo-Gen method for example, 2 mg of AGE-BSA were incubated with 25 mCi carrier-free [ 125 I] in an Iodogen-coated glass vial at room temperature for 45 min. In order to separate free from bound [ l25 I] , the sample was fractionated by Sephadex G-25M column chromatography and dialysis against PBS, until at least 98% of the 125 I was trichloroacetic acid-precipitable. The specific radioactivity of the labeled I25 I-AGE-BSA was between 8,000-15,000 cpm/ng protein.
  • BSA and AGE-BSA Sepharose were prepared by reacting either BSA or AGE-BSA (25 mg/ml) with CNBr-Sepharose gel (5 ml/g of dry powder) according to the manufacturers instructions, in coupling buffer (0.1 M NaHC0 3 , 0.5 M NaCl, pH 8.3). The mixture was rotated for 2 h at room temperature. Excess ligand was washed from the resin with coupling buffer and then with Tris-HCl buffer (0.1 M, pH 8.0) for 2 h at room temperature to block remaining active groups.
  • coupling buffer 0.1 M NaHC0 3 , 0.5 M NaCl, pH 8.3
  • the resin was then washed with three cycles of sodium acetate buffer (0.1 M, pH 4) containing NaCl (0.5 M) , followed by Tris-HCl buffer (0.1 M, pH 8) containing NaCl (0.5 M) , and stored at 4-8°C.
  • AGE-rat serum albumin (AGE-RSA) was prepared as described above, and radioiodinated to a specific activity of 8.3 X 10 5 cpm/ ⁇ g.
  • normal RSA was iodinated to a specific activity of 6.2 X 10 5 cpm/ ⁇ g.
  • Freshly drawn rat red blood cells (RBC) were labeled with 51 Cr to allow subsequent correction for tissue counts for blood-associated radioactivity.
  • Approximately 1 mCi of 51 Cr was added to 10 ml RBC, mixed thoroughly and allowed to incubate for 30 min at room temperature prior to washing with PBS containing 1% BSA and 0.1% dextrose until supernatant radioactivity was less than 1% of that in the packed RBC. Buffer was added to labeled RBC to obtain a hematocrit of 40% and the labeled RBC were used immediately.
  • the specificity of AGE-ligand uptake in various organs was assessed by injecting groups of animals with excess non- labeled AGE-BSA (5 g) two minutes prior to administration of 50 ⁇ g of 125 I-AGE-BSA. After 5, 20, and 60 minutes, 0.5 ml blood samples were collected, animals were sacrificed, and various organs and tissues were collected and counted for radioactivity. The red blood cells were lysed with water, and protein was precipitated with 20% TCA. The organs were weighed, homogenized with a hand homogenizer, protein was precipitated with 20% TCA and counted for radioactivity.
  • TBIR tissue-to-blood isotope ratio
  • Liver membranes were prepared according to the method of Thorn et al. with some modifications.
  • 14 grams of rat liver were homogenized in 80 ml TNE buffer [50 mM Tris-HCl buffer (pH 8.0), containing 150 mM NaCl, 0.1 mM EDTA, and 23 ⁇ g/ml phenylmethylsulfonyl fluoride (PMSF) ] and centrifuged for 10 min at 3000 x g.
  • the supernate was layered on top of a solution of 40% sucrose in TNE buffer, and centrifuged at 24,000 x g for 1 h at 4°C.
  • the membranes were collected from the interface with a Pasteur pipette.
  • the membrane preparation was solubilized in TNE buffer containing 2% Triton X-114 at 4°C and clarified by centrifugation for 30 min at 100,000 x g.
  • the supernate was then warmed to 30°C and the detergent phase, aqueous phase and detergent-insoluble pellet were separated according to the phase separation method described by Bordier.
  • the resulting detergent phase was either used directly for purification of AGE-binding proteins or diluted 1:10 with PBS containing 2% Triton X-100 and 2 mM PMSF. This material (D-phase) was frozen at -80°C until further use.
  • AGE-binding activity was determined by a modified version of solid-phase binding assay developed for the IL-1 receptor. Aliquots of detergent-solubilized membrane proteins were blotted onto grid-marked nitrocellulose (NC) membranes. The blots were dried at room temperature and could be stored at room temperature for several weeks without apparent loss of binding activity.
  • NC membranes were cut into small squares (0.9 cm 2 ) with the immobilized protein at the center and distributed in 24-well trays (Costar, Cambridge, MA) . Immobilized protein was reconstituted in PBS, pH 7.4, containing 0.5% Triton X-100 for 30-60 min at room temperature.
  • the blots were subsequently incubated in blocking buffer (PBS, pH 7.4, containing 2% BSA, 0.2% Triton X-100 and 1 mM MgCl 2 ) for 2 h with agitation at 4°C.
  • blocking buffer PBS, pH 7.4, containing 2% BSA, 0.2% Triton X-100 and 1 mM MgCl 2
  • Specific ligand binding was carried out by adding 50-100 nM 125 I-AGE-BSA directly to the blocking buffer and agitating at 4°C for a further 1.5 h.
  • the NC membranes were transferred to a new tray and rinsed quickly 3 times with PBS containing 0.2% Triton X-100, followed by two additional 10 min. washings with PBS. Ligand binding was then evaluated by autoradiography or gamma counting.
  • Ligand blotting SDS-PAGE and electro-blotting were performed as previously described. Proteins were electrophoretically separated on either 8-16% or 4-20% gradient polyacrylamide gels. After electro-blotting the proteins from the gel onto NC membranes, the blots were washed at 4°C overnight with PBS containing 0.2% Triton X-100. The blots were then incubated in blocking buffer for 3 h at 4°C with agitation. Ligand binding was performed by adding 10 nM l25 I-AGE-BSA to the blocking buffer. After 1.5-2 h at 4°C the blots were washed three times with blocking buffer for 1 min each and two times for 10 min each. After air drying, the ligand binding was evaluated by autoradiography.
  • the active fractions were pooled and dialyzed overnight against TNE buffer containing 1% CHAPS.
  • the PEI pool (160 mg protein, 80 ml) was then applied to a DEAE-cellulose column (2.5 x 20 cm) previously equilibrated with TNE/CHAPS/PMSF equilibration buffer.
  • the column was washed with 4 column volumes of equilibration buffer and proteins were eluted by a 200 ml linear gradient of 0.2-1.5 M NaCl in equilibration buffer.
  • the fractions which contained AGE-BSA binding activity were pooled and concentrated by ultrafiltration (Centricon 10, Amicon) .
  • the concentrated DEAE pool (80 mg protein) was cycled three times through a BSA-Sepharose 4B column (2 x 12 cm, 10 mg of BSA per ml of gel) , to eliminate proteins which bound to BSA.
  • the flow-through from this BSA-Sepharose column was then applied to an AGE-BSA-Sepharose 4B column (2 x 6 cm, 10 mg of AGE-BSA per ml of gel) and cycled twice.
  • the column was washed with .25 column volumes of PBS buffer, pH 7.4, containing 0.2% Triton X-100, and 1 mM PMSF.
  • the proteins bound to the AGE- BSA column were eluted with the step-wise addition of PBS buffer containing 1.5 M NaCl, 0.2% Triton X-100, and 1 mM PMSF. Each fraction was dialyzed against PBS containing 1 mM PMSF, concentrated by ultrafiltration (Centricon 30, Amicon) and analyzed for 125 I-AGE-BSA binding activity by the solid- phase binding assay.
  • Preparative electrophoresis was performed as described in detail elsewhere. In brief, 50 ⁇ g of the protein mixture which had been affinity purified over AGE-BSA was boiled for three min in sample buffer (0.03 M Tris-HCl, pH 6.8, 1% SDS, 5% glycerol, 0.015% Bromophenol Blue) in the presence of 0.1 M 2-mercaptoethanol and electrophoresed through 10% polyacrylamide gels in the presence of 0.1% SDS. The 60 kD and 90 kD protein bands were excised and electro-eluted (Elutrap, Schleicher & Schuell) in Tris buffer (25 mM, pH 8.5) containing glycine (192 mM) and 0.1% SDS, as described. Antibody generation.
  • hens were injected subcutaneously at multiple sites with a total of 100-150 ⁇ g of electrophoretically purified p60 or p90 in complete Freund's adjuvant (Pocono Rabbit Farm and Laboratory, Canadensis, PA.). On day 14 and 21 the hens were injected with an additional 60 ⁇ g of each protein in complete Freund's adjuvant. Further boosts of 80-100 ⁇ g of the corresponding proteins in incomplete Freund's adjuvant were given one month after the initial series. Eggs and serum from the chickens immunized with p60 or p90 proteins were separately collected.
  • Immunoglobulins from the yolks were extracted according to the method of Poison et al., while serum immunoglobulins were isolated by a combination of ammonium sulphate (30%) precipitation and DEAE cellulose chromatography.
  • the blots were probed with either anti-60 kD or anti-90 kD avian IgG or pre-immune chicken IgG (10 ⁇ g/ml) for 60 min at 4°C and then washed with TBS-t buffer three times, for 5 min each. The blots were then incubated with goat anti-chicken alkaline phosphatase conjugate (1:1000 dilution) for 1 hr at 4°C. Color development was achieved according to instructions of the manufacturer (Promega, Cleveland, OH) .
  • rat peritoneal macrophages were obtained from rats by washing the peritoneal cavity with 20 ml of PBS and were characterized by flow cytometry. Fluorescence Flow Cytometry. The expression of p60 and p90 AGE-binding proteins on rat monocytes and macrophages was determined by indirect immunofluorescence.
  • Single color cell staining was performed by incubating one million cells with biotinylated anti-p60 or anti-p90 primary antibodies at a final concentration of 5 ⁇ g/ml for 20 min at 4°C. Cells were washed in staining buffer (PBS, 3% FBS, 0.1% NaN 3 ) and then incubated with FITC-conjugated avidin (Becton Dickinson, Mountain View, CA) . Background fluorescence was determined by staining the cells with a relevant isotypic control antibody, biotinylated chicken IgG used in identical concentrations (5 ⁇ g/ml) .
  • FITC Fluorescence emission for FITC was detected by selectively collecting at 500-537 nm on at least 5000 labeled cells, gated to include monocytes/macrophages and to exclude lymphocytes, other non- monocytic cells and dead cells.
  • Paint-A-Gate software Consort 30, Becton Dickinson, Mountain View, CA
  • rat monocytes were treated with either 5 ⁇ g/ml biotinylated anti-p60 antibodies in the presence of 20-fold excess anti-p90 antibodies, or 5 ⁇ g/20 ⁇ l biotinylated anti-p90 in the presence of 20-fold excess anti- p60.
  • the antibody-treated cells were then labeled using FITC- avidin and analyzed by flow cytometry.
  • FIG. 6A shows the effect of increasing amounts of crude liver membrane proteins on AGE-ligand binding.
  • Total AGE-BSA binding increases in proportion to the amount of membrane proteins immobilized on the filters, whereas non-specific binding was negligible.
  • the AGE-binding kinetics of these membrane proteins after blotting onto nitrocellulose is shown in Figure 6B.
  • rat liver membrane proteins were solubilized in Triton X-114. After detergent phase- separation, the D-phase was subjected to chromatography on PEI-cellulose, DEAE-cellulose, BSA-Sepharose, and finally, AGE-BSA-Sepharose. After elution from the AGE-BSA Sepharose column, the fractions were assessed for AGE-binding activity by the solid-phase AGE binding method ( Figure 7) .
  • the antibodies to p60 and p90 were used to screen for the expression of these proteins on the surface of rat peripheral blood monocytes and peritoneal macrophages. FACS analyses which demonstrated the presence of each protein on the surface of both cell types are shown in Figure 9. Panels A and B illustrate flow cytometric detection of p60 and p90 on the surface of rat monocytes. Figure 9 also shows that the binding of either anti-p60 or anti-p90 to the monocyte cell surface was not affected by a 20-fold excess of the heterologously directed antibody (panels C and D respectively). Distinct binding of the anti-p60 and anti-p90 antibodies was also observed when the rat peritoneal resident macrophages were analyzed by flow cytometry ( Figure 9, panels E and F, respectively) . A small subgroup of highly fluorescent cells of an unspecified nature with a non-specific FITC staining pattern was also noted, using antibody as well as isotypic controls.
  • Rat liver membrane proteins were procured and prepared as described. Specific binding of AGE- BSA was determined by the solid phase binding assay.
  • Binding activity could not be determined due to the presence of SDS.
  • binding proteins have been distinguished from both the recently reported macrophage scavenger receptor for acetyl-LDL, a functional trimer composed of three 77 kD glycoprotein subunits; and from the binding proteins for formaldehyde- treated albumin with M r 's of 30 and 52 kD.
  • the p60 and p90 AGE-binding proteins were isolated from rat liver, upon the determination that this organ acts as a major filter for the in . vivo clearance of AGE-modified macromolecules; liver presents the highest capacity to specifically sequester AGE-proteins administered intravenously ( Figure 5) .
  • An isolation procedure, including elution of detergent-solubilized membrane proteins from an AGE-protein affinity matrix was devised, and the p60 and p90 AGE-binding proteins were found to co-purify.
  • the liver is a complex organ containing several cell types, including macrophages and endothelial cells, both of which have been shown to bear AGE-receptors.
  • macrophages also expressed a 60 kD AGE- binding protein, and whether there was any relationship between the macrophage 90 kD and the liver p90 AGE- binding proteins, specific polyclonal antibodies to liver p60 and p90 were developed.
  • This example presents the investigations and experiments that have resulted in the identification of the mesangial cell-derived AGE receptors of the present invention.
  • rat MCs Primary cultures of rat MCs were obtained from outgrowths of isolated rat glomeruli by Dr. M. Ganz (Yale University, N.Haven, Ct.) . In brief, rats were anesthetized with ether and the kidneys were excised under sterile conditions. After removing the kidney capsule, the kidney cortices were isolated, minced to a fine paste with a razor blade, and then pressed through serial stainless steel sieves (Tyler USA No. 140, 80, and 200) . Glomeruli were collected from the top of the 75 micrometer sieve. This process resulted in >98% pure glomeruli.
  • the glomeruli were then pelleted and resuspended in DMEM supplemented with 20% FBS, 5 ⁇ g/ml bovine insulin, 2 mM L-glutamine, and 40 ⁇ g/ml gentamicin.
  • the glomerular suspensions were plated onto tissue culture flasks and incubated at 37°C in 5% C0 2 . Primary cultures were allowed to grow for 3-4 weeks at which time the MCs were confluent. MCs were used between the fourth and ninth passages.
  • the purity of the rat MC populations was documented.
  • the MCs exhibited a uniform straplike appearance and stained positively for Thy 1-1 antigen, myosin and actin. They were sensitive to mito ycin C, a MC toxin, but were resistant to the aminonucleoside puromycin, an epithelial cell toxin. Fibroblast contamination was excluded by demonstrating the ability of the cells to grow in media in which L-valine had been substituted for D-valine. In addition, they stained negative for factor VIII and cytokeratin. Over the experimental period they continued to maintain a uniform stellate appearance.
  • Human MC were provided by Dr. J. Floege and Dr. K. Resch, (Hannover, FRG) .
  • normal human kidney tissue was obtained from nephrectomy specimens. Renal cortices were homogenized and glomeruli were isolated following passage through a series of graded sieves.
  • the glomeruli were then treated with bacterial collagenase (Worthington Biochemical Corporation, Freehold, NJ) at 37°C for 30 minutes, and after extensive washing the glomerular remnants were plated onto tissue culture flasks in RPMI 1640, supplemented with 20% FBS, 2 mM L-glutamine, 2 mM sodium pyruvate, 5 ⁇ g/ml bovine insulin, 5 ⁇ g/ml human transferrin, 1% (v/v) non-essential amino acids, and gentamicin. Cellular outgrowths appeared between days 5-8, and all experiments were performed using cells between the fourth and tenth passage. The purity of the MC population was demonstrated.
  • immunofluorescent staining demonstrated prominent intracellular staining for smooth muscle cell myosin, MHC class I antigen, vimentin, collagen IV, and fibronectin.
  • AGE- bovine serum albumin (BSA) and AGE-ribonuclease were made by incubating BSA and bovine ribonuclease (Sigma Chemical Co, St. Louis, MO) with 0.5 M glucose-6-phosphate (G6P) , at 37°C for 4 to 6 weeks in a 10 mM PBS buffer, pH 7.4 , in the presence of protease inhibitors and antibiotics. Unincorporated glucose was removed by dialysis against IX PBS. The concentration of AGE-BSA was determined and the concentration of ribonuclease was determined spectrophotometrically.
  • BSA bovine serum albumin
  • G6P glucose-6-phosphate
  • AGE formed on either BSA or ribonuclease was assessed based on characteristic absorption and fluorescence spectra (emission at 450 nm, excitation at 390 nm) and quantitated by a radioreceptor assay using intact RAW 264.7 cells grown in 96-well plates.
  • AGE-BSA contained approximately 70 AGE U/mg (one unit of AGE is defined as the concentration of unknown agent required to produce 50% inhibition of standard ,25 I- AGE-BSA binding) and AGE-ribonuclease contained 62 AGE U/mg.
  • AGE-BSA was iodinated with carrier-free-' 25 I by the IODO-GEN method (Bio-Rad) of Fraker and Speck. Samples were dialyzed against PBS until >95% of radioactivity was trichloroacetic acid (TCA)-precipitable and the samples were iodide free.
  • TCA trichloroacetic acid
  • AGE-matrices 6-well plates coated with rat tail collagen, type I, human fibronectin, and polylysine were purchased from Collaborative Research, Inc. (Bedford, MA) .
  • AGE-matrices were produced by incubating the various matrix coated plates in 0.5 M G6P, at 37°C for 2-3 weeks in 10 mM PBS buffer (pH 7.4), as described for AGE-BSA.
  • Control matrices were incubated under identical conditions in buffer alone. Following incubation, the plates were washed extensively with IX PBS. The amount of adhered collagen I was determined using a hydroxyproline assay, while adhered fibronectin and laminin were determined by the method of Lowry et al.
  • Membrane preparation Rat and human MCs were grown to confluency in 150 mm petri dishes. Cells were detached from the plates by PBS containing 3% EDTA and protease inhibitors (2 mM phenyl ethylsulfonyl-fluoride [PMSF] , 10 ⁇ g/ml aprotinin, 5 ng/ml pepstatin, and 1 mM 1,10- phenanthroline) .
  • PMSF phenyl ethylsulfonyl-fluoride
  • Binding studies were performed according to the method of Schneider et al. and Daniel et al. with minor modifications. 10-20 ⁇ g of MC membrane protein was dot-blotted onto nitrocellulose filters. The nitrocellulose filters were then cut and each dot was placed in a separate well of a 24-well plate. Following blocking of the filters for 1 hour at 4°C in PBS containing 1.5% BSA, binding studies were initiated by adding various concentrations of radioactive ligand to the individual wells.
  • nitrocellulose filters were washed 3 times with ice-cold IX PBS, and radioactivity bound was quantitated using a Packard Tricarb Scintillation counter.
  • Specific binding was defined as the difference between total binding (radioligand incubated with membrane protein alone) , and nonspecific binding (cells incubated with radiolabelled ligand plus 100-fold excess unlabelled ligand) . Scatchard analysis of the data was performed to determine the binding affinity constant and the receptor number. Competition studies were performed in a similar manner to the binding studies, with the exception that the nitrocellulose filters were preincubated with the competitor for 1 hour before adding the radiolabelled ligand.
  • Binding studies were also performed on confluent MCs in 6-well plates. The studies were performed in 1 ml of RPMI-1640 at 4°C following the addition of various concentrations of radioactive ligand. After 2 hours of binding, the radioligand-containing medium was removed, and the cells were washed with ice-cold PBS. The cell monolayer was then disrupted with 1% triton X-100, and the cell-associated radioactivity was quantitated.
  • Protein concentration was determined by the method of Bradford. Specific binding was determined in an identical manner to that described above for the filter binding assay.
  • Ligand blotting MC membrane preparations (5 ug aliquots) were electrophoresed on a nonreducing SDS-PAGE (10%) , and then electroblotted onto a nitrocellulose filter. Following blocking for 1 hour in a solution of PBS containing 1.5% BSA, the nitrocellulose filter was probed with 125 I- AGE-BSA in the presence of 100-fold excess of either BSA or AGE-BSA. The blot was washed 3 times with IX PBS and exposed to Kodak XAR-5 film at -80°C.
  • MC uptake and degradation was performed with a minor modification of previously described procedures. Briefly, MCs were grown to confluency in 6-well plates in DMEM containing 20% FBS and insulin. MC accumulation of radioactive ligand
  • AGE-BSA was assessed by incubating cells with various concentrations of 125 I-AGE-BSA, in the presence and absence of 100-fold excess of unlabelled AGE-BSA, for 4 hours at 37°C . After washing the cells 3 times with ice-cold PBS, the cells were solubilized in 1% Triton X-100 for 45 minutes at room temperature, and the amount of cell associated radioactivity was determined. Specific uptake was defined by the same criteria as used for the MC binding studies. Protein concentration was determined by the method of Bradford. Degradation was determined by measuring TCA-soluble radioactivity in the aspirated medium.
  • Proliferation assays Rat MCs in DMEM containing 20% FBS were plated at 1X10 4 cells/well onto flat-bottom 96-well microtitre plates, which had been pre-coated with different amounts of either AGE-modified or unmodified matrix proteins. 24 hours later, the cells were washed with IX PBS and incubated for an additional 48 hrs in medium containing 0.3% FBS. The cells were then labelled with 2 uCi of ( 3 H) thymidine (Amersham Corp., Arlington Heights,IL) for 18-24 hours, following which the supernatants were aspirated and the cells in each well were harvested onto glass fiber filters with an automated cell harvester. The amount of ( 3 H) thymidine incorporated was determined with a Beckman Scintillation Counter.
  • Fibronectin production Human MCs in RPMI-1640 medium supplemented with 20% FBS were plated at 2 X 10 5 cells per well onto 6-well plates which had been coated with glucose-modified or unmodified matrix proteins. After 24 hours, the cells were washed with IX PBS and incubated in medium containing 0.3% FBS for 48 hours. The cells were then labeled in methionine free medium for 3 hours with 200 uCi of (35S) methionine and cysteine (Translabel, ICN) .
  • the medium was removed and the cell monolayers were washed with cold IX PBS.
  • the monolayers were extracted with 0.5 ml of a 1M urea solution containing ImM dithiothreitol (DTT) , 10 mM Tris-HCL (pH) 7.4), 10 mM EDTA, and 2 mM PMSF.
  • Fibronectin was then isolated from the medium and matrix by immunoprecipitation with an IgG purified anti-human fibronectin antibody (Cappel, Malvern, PA) .
  • Anti-fibronectin antibody was added to the samples and incubated overnight at 4°C. To insure than any differences in fibronectin synthesis were not due to different number of cells/well, equal amounts of TCA- precipitable counts were immunoprecipitated from each well.
  • the immune complexes were isolated using protein A-Sepharose beads (Pharmacia) .
  • fibronectin was released by heating at 100°C for 5 minutes in SDS-PAGE sample buffer, and analyzed by gel electrophoresis and fluorography. The amount of fibronectin from each sample was quantitated by slicing the fibronectin band from the gel and determining (35S) methionine and cysteine incorporation in a liquid scintillation counter.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention se rapporte à un récepteur de produits finaux de glycosylation avancée, qui peut être dérivé des cellules de mésangium ou des membranes du foie de rat, et qui comprend spécifiquement certaines protéines présentant respectivement des masses moléculaires d'environ 90 kD, 60 kD, 50 kD, 40 kD et de 30 à 35 kD, déterminées par migration au cours de l'electrophorèse sur gel de polyacrilamide en présence de SDS. Des séquences N-terminales partielles ont été déterminées, et des agents, des compositions et des procédés diagnostiques et thérapeutiques sont décrits.
PCT/US1992/007155 1991-08-23 1992-08-24 Recepteurs de produits finaux de glycosylation avancee et leurs utilisations WO1993004086A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US749,438 1991-08-23
US07/749,444 US5202424A (en) 1984-03-19 1991-08-23 Mesangial cell-derived receptors for advanced glycosylation endproducts and uses thereof
US07/749,438 US5585344A (en) 1984-03-19 1991-08-23 Liver-derived receptors for advanced glycosylation endproducts and uses thereof
US749,444 1991-08-23

Publications (1)

Publication Number Publication Date
WO1993004086A1 true WO1993004086A1 (fr) 1993-03-04

Family

ID=27115120

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/007155 WO1993004086A1 (fr) 1991-08-23 1992-08-24 Recepteurs de produits finaux de glycosylation avancee et leurs utilisations

Country Status (2)

Country Link
AU (1) AU2506792A (fr)
WO (1) WO1993004086A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993016717A1 (fr) * 1992-02-25 1993-09-02 The Rockefeller University Procede et agents favorisant la cicatrisation des blessures
WO1994020083A1 (fr) * 1993-03-11 1994-09-15 The Picower Institute For Medical Research Glycosylation de lipides et de particules contenant des lipides, procedes diagnostiques et therapeutiques et produits derives
WO1996031537A1 (fr) * 1995-04-05 1996-10-10 The Picower Institute For Medical Research Agents se liant a des produits finals de glycosylation evolues et leurs methodes d'utilisation
WO1997039125A1 (fr) * 1996-04-16 1997-10-23 Schering Aktiengesellschaft Patente Anticorps diriges contre le recepteur de produits terminaux d'une glycosylation avancee, et utilisations de ces anticorps
WO1997039121A1 (fr) * 1996-04-16 1997-10-23 Schering Aktiengesellschaft Peptides du recepteur de produits terminaux d'une glycosylation avancee, et utilisation de ces peptides
US5700447A (en) * 1992-05-21 1997-12-23 The Picowder Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5733933A (en) * 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5733524A (en) * 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5766856A (en) * 1984-03-19 1998-06-16 The Picower Institute For Medical Research Diagnostic method for evaluating advanced glycosylation endproducts using MAC-2 receptor
US5801200A (en) * 1984-03-19 1998-09-01 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5855882A (en) * 1995-04-05 1999-01-05 The Picower Institute For Medical Research Methods for inhibiting the cross-linking of advanced glycosylation endproducts
EP1609862A1 (fr) * 1996-10-25 2005-12-28 Peter Mose Larsen Protéines médiatrices de diabetes et leurs utilisations thérapeutiques
US8043616B2 (en) 2004-09-27 2011-10-25 Centocor, Inc. sRAGE mimetibody, compositions, methods and uses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF CELLULAR BIOCHEMISTRY vol. SUP, no. 14E, 1990, NEW YORK, US page 76 M. KIRSTEIN ET AL. 'Advanced glycosylation endproduct (AGE) binding to its specific receptor stimulates increase in EGF and EGF receptor mRNAs: Role in tissue remodeling.' *
JOURNAL OF EXPERIMENTAL MEDICINE vol. 174, no. 3, 1 September 1991, NEW YORK, US pages 515 - 524 Z. YANG ET AL. 'Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: Relationship to macrophage receptor for glucose-modified proteins.' *
JOURNAL OF EXPERIMENTAL MEDICINE vol. 174, no. 4, 1 October 1991, NEW YORK, US pages 931 - 939 E. SKOLNIK ET AL. 'Human and rat mesangial cell receptors for glucose-modified proteins: Potential role in kidney tissue remodelling and diabetic nephropathy.' *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801200A (en) * 1984-03-19 1998-09-01 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5733933A (en) * 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5733524A (en) * 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5766856A (en) * 1984-03-19 1998-06-16 The Picower Institute For Medical Research Diagnostic method for evaluating advanced glycosylation endproducts using MAC-2 receptor
WO1993016717A1 (fr) * 1992-02-25 1993-09-02 The Rockefeller University Procede et agents favorisant la cicatrisation des blessures
US5780615A (en) * 1992-05-21 1998-07-14 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles and diagnostic and therapeutic methods and materials derived therefrom
US5869534A (en) * 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US5700447A (en) * 1992-05-21 1997-12-23 The Picowder Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
WO1994020083A1 (fr) * 1993-03-11 1994-09-15 The Picower Institute For Medical Research Glycosylation de lipides et de particules contenant des lipides, procedes diagnostiques et therapeutiques et produits derives
US5861238A (en) * 1995-04-05 1999-01-19 The Picower Institute For Medical Research Methods for partitioning advanced glycosylation endproducts
US5855882A (en) * 1995-04-05 1999-01-05 The Picower Institute For Medical Research Methods for inhibiting the cross-linking of advanced glycosylation endproducts
WO1996031537A1 (fr) * 1995-04-05 1996-10-10 The Picower Institute For Medical Research Agents se liant a des produits finals de glycosylation evolues et leurs methodes d'utilisation
US5891341A (en) * 1995-04-05 1999-04-06 The Picower Institute For Medical Research Compositions and devices for partitioning advanced glycosylation endproducts, and methods of their use
US5962245A (en) * 1995-04-05 1999-10-05 The Picower Institute For Medical Research Methods for detecting the presence of advanced glycosylation endproducts
WO1997039121A1 (fr) * 1996-04-16 1997-10-23 Schering Aktiengesellschaft Peptides du recepteur de produits terminaux d'une glycosylation avancee, et utilisation de ces peptides
WO1997039125A1 (fr) * 1996-04-16 1997-10-23 Schering Aktiengesellschaft Patente Anticorps diriges contre le recepteur de produits terminaux d'une glycosylation avancee, et utilisations de ces anticorps
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
EP1609862A1 (fr) * 1996-10-25 2005-12-28 Peter Mose Larsen Protéines médiatrices de diabetes et leurs utilisations thérapeutiques
US8043616B2 (en) 2004-09-27 2011-10-25 Centocor, Inc. sRAGE mimetibody, compositions, methods and uses

Also Published As

Publication number Publication date
AU2506792A (en) 1993-03-16

Similar Documents

Publication Publication Date Title
US5852174A (en) Antibodies to liver derived receptors for advanced glycosylation endproducts and uses therefor
Yang et al. Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins.
US5202424A (en) Mesangial cell-derived receptors for advanced glycosylation endproducts and uses thereof
US5316754A (en) In vitro assay of mesangial cell-derived receptors for advanced glycosylation endproducts
US5863739A (en) Assay and kit for the detection of α platelet derived growth factor receptor
FI102181B (fi) Menetelmä ICAM-1 (solujen välisen kiinnikemolekyylin) saamiseksi oleel lisesti puhtaassa muodossa
EP2487186B1 (fr) Structures immunorégulatrices pour protéines naturellement produites
WO1995015180A1 (fr) Anticorps imitant les effets des neurotrophines
EP0925503B1 (fr) Substances et methodes relatives au diagnostic et au traitement du diabete et de l'obesite
JPH10509149A (ja) 感覚および運動ニューロンにより誘導される因子（ｓｍｄｆ）
JPH10503081A (ja) Ｔｉｅ２／ｔｅｋレセプタ細胞外ドメインに結合する免疫相互作用性分子
WO1993004086A1 (fr) Recepteurs de produits finaux de glycosylation avancee et leurs utilisations
WO1996003502A2 (fr) Proteines derivees de muc1 destinees au diagnostic, a l'imagerie et a la therapie du cancer humain
US20050026826A1 (en) Feline proinsulin, insulin and constituent peptides
US6423314B2 (en) Tumor derived carbohydrate binding protein
JPH07224089A (ja) ｎｅｕレセプターの刺激因子
EP1086136A1 (fr) Anticorps monoclonaux specifiques de produits finaux de glycosylation avancee derives de groupes guanidino dans des echantillons biologiques
EP0574414B1 (fr) FACTEURS DE CROISSANCE LIGANDS QUI SE LIENT AU RECEPTEUR PROTEIQUE erbB-2 ET INDUISENT DES REPONSES CELLULAIRES
EP1009431A1 (fr) Anticorps contre le recepteur de type 2 (tr2) du facteur de necrose des tumeurs humain
US5766856A (en) Diagnostic method for evaluating advanced glycosylation endproducts using MAC-2 receptor
JP2792651B2 (ja) ヒト膵臓癌に対するモノクローナル抗体
WO1993017045A1 (fr) Nouveau facteur de croissance serique
AU689232B2 (en) An immunointeractive molecule which binds the (TIE)2/TEK receptor extracellular domain
KR100883860B1 (ko) 에리스로포이에틴에 의해 수반되는 고혈압 방지를 위한조성물 및 방법
US20020102258A1 (en) Human tumor necrosis factor receptor-like 2 (TR2) antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA